Dendritic cell vaccination of patients with metastatic colorectal cancer

Danish Medical Bulletin

Volumn 57, Issue 9, 2010, Pages

  Burgdorf, Stefan K ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CYTOKINE; DENDRITIC CELL VACCINE; TUMOR ANTIGEN; BIOLOGICAL MARKER; CANCER VACCINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL TRANSFER; CELLULAR IMMUNITY; COLORECTAL CANCER; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; T LYMPHOCYTE; ACTIVE IMMUNIZATION; BLOOD; CLINICAL TRIAL; COLORECTAL TUMOR; DENDRITIC CELL; IMMUNOLOGY; MIDDLE AGED; PASSIVE IMMUNIZATION; TUMOR CELL LINE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CANCER VACCINES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED;

EID: 77957682296     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Cancerregisteret 2005 og 2006. Nye tal fra Sundhedsstyrelsen. 2008.
3. RM. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005; 10 Suppl 3:40-48.
4. Ju JH, Chang SC, Wang HS, Yang SH, Jiang JK et al. Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years. Int J Colorectal Dis 2007; 22:855-62.
5. Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: a population based study. Eur J Cancer 2006; 42:1848-57.
6. McWilliams RR, Goetz MP, Morlan BW, Salim M, Rowland KM et al. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6:516-21.
7. Nakata B, Sowa M, Tsuji A, Kamano T, Sasaki K et al. Continuous infusion of 5-fluorouracil with versus without lowdose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study. J Exp Clin Cancer Res 2007; 26:51-60.
8. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1957; 1:841-7.
9. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121:1-14.
10. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55:329-33.
11. Rygaard J, Povlsen CO. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1974; 82:99-106.
12. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974; 183:534-6.
13. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1:447-56.
14. Street SE, Cretney E, Smyth MJ. Perforin and interferongamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97:192-7.
15. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60:183-9.
16. Pham SM, Kormos RL, Landreneau RJ, Kawai A, Gonzalez-Cancel I et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995; 60:1623-6.
17. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006; 12:3064-9.
18. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62.
19. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64:529-64.
20. Yuk JM, Shin DM, Yang CS, Kim KH, An SJ et al. Role of apoptosis-regulating signal kinase 1 in innate immune responses by Mycobacterium bovis bacillus Calmette-Guerin. Immunol Cell Biol 2009; 87:100-7.
21. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980; 124:38-40.
22. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG et al. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev 2000;CD001986.
23. Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg 2004; 198:685-96.
24. Huber CH, Wolfel T. Immmunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 2004; 130:367-74.
25. Yip D, Strickland AH, Karapetis CS, Hawkins CA, Harper PG. Immunomodulation therapy in colorectal carcinoma. Cancer Treat Rev 2000; 26:169-90.
26. Saif MW, Kang SP, Chu E. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Oncology 2006; 20:11-9.
27. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007; 26:3661-78.
28. Halak BK, Maguire HC, Jr., Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999; 59:911-7.
29. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10:281-7.
30. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001; 250:462-75.
31. Aulitzky WE, Huber C, Peschel C. Cytokine therapy of neoplastic and inflammatory disease. Int Arch Allergy Immunol 1993; 101:221-6.
32. Hill HC, Conway TF, Jr., Sabel MS, Jong YS, Mathiowitz E et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002; 62:7254-63.
33. Holcombe RF, Li A, Stewart RM. Levamisole and interleukin- 2 for advanced malignancy. Biotherapy 1998; 11:255-8.
34. Wilson JA. Tumor necrosis factor alpha and colitisassociated colon cancer. N Engl J Med 2008; 358:2733-4.
35. Donskov F, von der MH. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24:1997-2005.
36. Donskov F, Middleton M, Fode K, Meldgaard P, Mansoor W et al. Two randomised phase II trials of subcutaneous interleukin- 2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. Br J Cancer 2005; 93:757-62.
37. McDermott DF. The application of high-dose interleukin-2 for metastatic renal cell carcinoma. Med Oncol 2009; 26:13-7.
38. Gebbia V, Testa A, Majello E, Cannata G, Tirrito ML et al. Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma. Anticancer Drugs 1996; 7:386-91.
39. Mitchell MS. Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 2003; 52:686-92.
40. Nicolini A, Carpi A, Ferrari P, Sagripanti A, Anselmi L. A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. Biomed Pharmacother 1998; 52:311-6.
41. Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007; 13:5857-66.
42. Moosmann N, Heinemann V. Cetuximab plus oxaliplatinbased chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther 2008; 8:319-29.
43. Mahtani RL, Macdonald JS. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist 2008; 13:39-50.
44. Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5:171-93.
45. Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004; 22:858-65.
46. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 35:2039-49.
47. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-9.
48. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
49. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-76.
50. Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Adoptive T-cell therapy for the treatment of solid tumours. Expert Opin Biol Ther 2002; 2:55-66.
51. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-15.
52. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308.
53. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9.
54. Riddell SR. Engineering antitumor immunity by T-cell adoptive immunotherapy. Hematology Am Soc Hematol Educ Program 2007:250-256.
55. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41:483-93.
56. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90:297-339.
57. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000; 46:S52-S61.
58. Huang H, Hao S, Li F, Ye Z, Yang J et al. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 2007; 120:148-59.
59. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4:11-22.
60. Nembrini C, Abel B, Kopf M, Marsland BJ. Strong TCR signaling, TLR ligands, and cytokine redundancies ensure robust development of type 1 effector T cells. J Immunol 2006; 176:7180-8.
61. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007; 117:1119-27.
62. Moingeon P. Strategies for designing vaccines eliciting Th1 responses in humans. J Biotechnol 2002; 98:189-98.
63. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002; 196:619-28.
64. Dredge K, Marriott JB, Todryk SM, Dalgleish AG. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 2002; 51:521-31.
65. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54:187-207.
66. Mocellin S, Rossi CR, Lise M, Nitti D. Colorectal Cancer Vaccines: Principles, Results, and Perspectives. Gastroenterology 2004; 127:1821-37.
67. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008; 68(3):889-892.
68. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5:681-9.
69. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1:362-8.
70. Romani N, Gruner S, Brang D, Kampgen E, Lenz A et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
71. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223:1-15.
72. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375:151-5.
73. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained bygranulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18.
74. Adema GJ, Hartgers F, Verstraten R, de VE, Marland G et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997; 387:713-7.
75. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
76. Whiteside TL, Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 2004; 53:240-8.
77. de V, I, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63:12-7.
78. Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999; 48:118-22.
79. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004; 53:275-306.
80. Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B. Regulatory T-cell response and tumor vaccineinduced cytotoxic T lymphocytes in human melanoma. Hum Immunol 2004; 65:794-802.
81. Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U. Immunological monitoring of cancer vaccine therapy. Expert Opin Biol Ther 2004; 4:1677-84.
82. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15.
83. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003; 21:873-86.
84. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007; 30:762-72.
85. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005; 16:847-62.
86. Kirkin AF, thor SP, Hansen MR, Barfoed A, Dzhandzhugazyan KN et al. Establishment of gp100 and MART-1/Melan-Aspecific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones. Cancer Immunol Immunother 1999; 48:239-46.
87. Kirkin AF, Petersen TR, Olsen AC, Li L, thor SP et al. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother 1995; 41:71-81.
88. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
89. Bjorner JB, Thunedborg K, Kristensen TS, Modvig J, Bech P. The Danish SF-36 Health Survey: translation and preliminary validity studies. J Clin Epidemiol 1998; 51:991-9.
90. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-83.
91. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999; 80:495-503.
92. Klein G, Klein E. Surveillance against tumors--is it mainly immunological? Immunol Lett 2005; 100:29-33.
93. Yu P, Lee Y, Wang Y, Liu X, Auh S et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 2007; 179:1960-8.
94. Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007; 17:275-87.
95. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353:345-50.
96. Cubas R, Li M, Chen C, Yao Q. Colorectal cancer: new advances in immunotherapy. Cancer Biol Ther 2007; 6:11-7.
97. Duffy MJ, van DA, Haglund C, Hansson L, Holinski-Feder E et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43:1348-60.
98. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313-27.
99. Nielsen HJ, Christensen IJ, Brunner NA. [Serological markers of colorectal cancer]. Ugeskr Laeger 2005; 167:4163-7.
100. Ferroni P, Palmirotta R, Spila A, Martini F, Formica V et al. Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. Oncology 2006; 71:176-84.
101. Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 2008; 15:3433-9.
102. Kosmider S, Stella DL, Field K, Moore M, Ananda S et al. Preoperative Investigations for Metastatic Staging of Colon and Rectal Cancer across Multiple Centres- What is Current Practice? Colorectal Dis 2009; 11:592-600.
103. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E et al. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009; 18:15-24.
104. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8:156-64.
105. Moller SN, Vejgaard S, I, Ornbjerg WS, Schrohl AS, Dowell B et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008; 43:774-86.
106. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and - 4 in colorectal cancer. Int J Cancer 2007; 121:714-23.
107. Kim TD, Song KS, Li G, Choi H, Park HD et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006; 6:211.
108. Hammer JH, Basse L, Svendsen MN, Werther K, Brunner N et al. Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer. Colorectal Dis 2006; 8:168-72.
109. Holten-Andersen MN, Hansen U, Brunner N, Nielsen HJ, Illemann M et al. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer 2005; 113:198-206.
110. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000; 20:1085-91.
111. Nielsen HJ, Brunner N, Frederiksen C, Lomholt AF, King D et al. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol 2008; 43:242-8.
112. Sorensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 2007; 13:4117-22.
113. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 2004; 23:119-35.
114. J, Ward S, Dalgleish A. Cell based cancer vaccines: regulatory and commercial development. Vaccine 2007; 25 Suppl 2:B35-B46.
115. Zhang T, Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother 2009; 58:475-92.
116. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007; 13:4487-94.
117. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30:1-15.
118. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38:1000-15.